Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Moodys
Mallinckrodt
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Odalasvir

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Odalasvir: Patents, clinical trial progress, indications

Odalasvir is an investigational drug.

There have been 12 clinical trials for Odalasvir. The most recent clinical trial was a Phase 1 trial, which was initiated on April 4th 2017.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Pharmaceutical K.K., and [disabled in preview].

There are six US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for Odalasvir
TitleSponsorPhase
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic FunctionJanssen Research & Development, LLCPhase 1
A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy ParticipantsJanssen Research & Development, LLCPhase 1
A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) InfectionJanssen Research & Development, LLCPhase 3

See all Odalasvir clinical trials

Clinical Trial Summary for Odalasvir

Top disease conditions for Odalasvir
Top clinical trial sponsors for Odalasvir

See all Odalasvir clinical trials

US Patents for Odalasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, INC. (New Haven, CT)   Start Trial
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections ACHILLION PHARMACEUTICALS, INC. (New Haven, CT)   Start Trial
Odalasvir   Start Trial Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Odalasvir

Drugname Country Document Number Estimated Expiration Related US Patent
Odalasvir Australia 2012262338 2031-05-27   Start Trial
Odalasvir Australia 2017201535 2031-05-27   Start Trial
Odalasvir Brazil 112013030045 2031-05-27   Start Trial
Odalasvir Canada 2837481 2031-05-27   Start Trial
Odalasvir China 103561739 2031-05-27   Start Trial
Odalasvir China 105801467 2031-05-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Boehringer Ingelheim
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.